Indian Pharma exports expected double to USD 65 billion by 2030: Report
India's pharmaceutical exports are projected to double to USD 65 billion by 2030 and reach an impressive USD 350 billion by 2047, according to a report. The Bain & Company's report, 'Healing the World: Roadmap for Making India a Global Pharma Exports Hub', highlights India can potentially secure a position among the top five pharmaceutical exporting nations globally by diversifying its product offerings.
Currently, India stands as the world’s largest supplier of generic drugs, accounting for one in five generic medications sold worldwide. However, despite this dominance, the country ranks 11th in terms of export value.
The findings in the report were formulated in collaboration with Indian Pharmaceutical Alliance (IPA), Indian Drugs Manufacturers' Association (IDMA), and Pharmexcil.
"The transition from volume-based to value-led growth is essential for Indian pharma to secure its rightful place in the global market. Innovation, including the shift towards specialty generics, biosimilars, and novel products, will be the key to India's pharmaceutical future," Sriram Shrinivasan, Partner, Bain & Company, said.
With the right focus on quality, regulation, access to global markets, talent, and entrepreneurial innovation, India can rise to be among the top-five pharma exporters globally by 2047, he added.
Indian Drug Manufacturers' Association (IDMA) National President Viranchi Shah highlighted that India can become one of the leaders in pharma exports, but needs strategic interventions.
Bulk drug parks are key to API export growth -- India must scale efforts to revive and strengthen its API industry while improving energy supply, waste treatment, and road connectivity, he added.
Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain said India aims to become a USD 30-35 trillion economy by 2047 and to achieve that, the pharmaceutical industry must excel on all fronts.
"It is crucial to double down on Indian pharmaceutical exports, which currently account for 6 per cent of India's total merchandise exports by value," he added.
The report stressed that key industry segments like APIs, biosimilars, and generic formulations were poised to grow significantly going ahead.
Besides, collaboration between the government and private sector crucial for global competitiveness, it highlighted.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.